title: Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.
abstract: OBJECTIVE
  To compare the effects of two different methods for initiating atomoxetine in terms of the incidence of early adverse events.
  
  
  METHODS
  Data on atomoxetine treatment-emergent adverse events in youths, ages 6 to 18 years, were analyzed from five randomized, double-blind, placebo-controlled, acute-phase studies. Two studies involve once-daily dosing and titration to 1.2 mg/kg/day over 3 days (fast/once daily, n = 234) and three involve twice-daily dosing and titration to a dose of 1.2 mg/kg/day over at least 2 weeks (slow/twice daily, n = 213).
  
  
  RESULTS
  During the first 2 weeks of treatment, fast/once daily titration patients showed higher rates of spontaneously reported adverse events than patients in the slow/twice daily titration group. This included decreased appetite (14.3% versus 8.0%, p = .036) and somnolence (14.3% versus 4.2%, p < .001). Patients in the slow/twice daily group showed higher rates of headache (7.4% versus 16.9%, p = .003). Analysis of the studies' overall acute treatment phases revealed significantly higher rates in the fast/once daily group only for somnolence. No significant differences were seen in completion rates or reasons for discontinuation.
  
  
  CONCLUSIONS
  When starting atomoxetine, the risk of adverse events within the first few weeks of treatment may be lower if patients are dosed twice daily and titrated to the 1.2 mg/kg/day total daily dose over the first week.
authors: Dr. Greenhill is with The New York State Psychiatric Institute/Columbia University, New York; Dr. Newcorn is with Mount Sinai School of Medicine, New York; Drs. Gao and Feldman are with Lilly Research Laboratories, Eli Lilly and Company, Indianapolis. Electronic address: greenhil@child.cpmc.columbia.edu.
authors: Laurence L
authors: LL
authors: Greenhill
authors: Dr. Greenhill is with The New York State Psychiatric Institute/Columbia University, New York; Dr. Newcorn is with Mount Sinai School of Medicine, New York; Drs. Gao and Feldman are with Lilly Research Laboratories, Eli Lilly and Company, Indianapolis.
authors: Jeffrey H
authors: JH
authors: Newcorn
authors: Dr. Greenhill is with The New York State Psychiatric Institute/Columbia University, New York; Dr. Newcorn is with Mount Sinai School of Medicine, New York; Drs. Gao and Feldman are with Lilly Research Laboratories, Eli Lilly and Company, Indianapolis.
authors: Haitao
authors: H
authors: Gao
authors: Dr. Greenhill is with The New York State Psychiatric Institute/Columbia University, New York; Dr. Newcorn is with Mount Sinai School of Medicine, New York; Drs. Gao and Feldman are with Lilly Research Laboratories, Eli Lilly and Company, Indianapolis.
authors: Peter D
authors: PD
authors: Feldman
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D011437:Propylamines / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index
chemical_list: D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride